Hapvida Participacoes e Investimentos (HAPV3) Q4 2025 earnings summary

Executive summary

• Q4 2025 results missed expectations due to higher MLR, weak member growth, and operational challenges, especially in less mature and competitive regions; mature markets remained resilient.

• Net revenue for 4Q25 was R$7.9 billion, up 1.8% sequentially and 5.9% year-over-year; full-year 2025 revenue reached R$30.86 billion.

• Adjusted EBITDA for 4Q25 was R$714 million (9.0% margin), down 4.4% sequentially and 32.8% year-over-year; adjusted net income was R$181 million.

• CEO succession is underway, with Luccas Adib set to take over, emphasizing continuity and renewal; leadership transition focuses on capital discipline and digital transformation.

• Reported a consolidated net loss of R$237.6 million for 2025, reversing a net profit in 2024, mainly due to higher costs and financial expenses.

Financial highlights

• Q4 2025 saw a net loss of 140,000 health beneficiaries, with gross additions over 600,000 but high churn; dental beneficiaries increased by 23,000 sequentially.

• Cash MLR was 75.5% in Q4 2025, up 0.2 p.p. quarter-on-quarter and 4.5 p.p. year-over-year, driven by higher utilization and fixed costs from new units.

• Adjusted EBITDA was R$714 million; excluding non-recurring effects, EBITDA was R$556 million.

• Adjusted net income for 4Q25 was R$181 million (2.3% margin), but only R$76.4 million (1.0% margin) excluding one-offs.

• CapEx for Q4 was R$419 million; full-year 2025 CapEx was R$1,234 million, down 32.3% year-over-year.

• Free cash at year-end ranged from R$5.6 billion to R$8.19 billion, covering amortizations for 4–5 years.

• Net debt increased to R$5.18 billion, with leverage at 1.32x EBITDA LTM.

Outlook and guidance

• 2026 priorities: rational growth in lagging markets, margin recovery via higher own network occupancy and care management, and tighter capital discipline.

• No significant new unit openings planned for 2026; focus on optimizing existing assets and possibly shutting down underperforming units.

• Sequential improvement in MLR expected in Q1 2026 as utilization normalizes; early 2026 data shows positive trends.

• CapEx to be stricter, with focus on ROI and selective investments.

• Management affirmed going concern, citing sufficient liquidity and positive net working capital.